Mineralys Therapeutics (NASDAQ:MLYS) Director Alexander Gold Sells 12,742 Shares of Stock

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Director Alexander Gold sold 12,742 shares of the stock in a transaction that occurred on Thursday, November 13th. The stock was sold at an average price of $46.50, for a total value of $592,503.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Mineralys Therapeutics Stock Performance

Shares of MLYS stock opened at $44.29 on Friday. Mineralys Therapeutics, Inc. has a fifty-two week low of $8.24 and a fifty-two week high of $47.65. The firm has a market cap of $3.51 billion, a P/E ratio of -15.01 and a beta of 0.40. The business’s 50 day moving average price is $40.05 and its 200-day moving average price is $23.78.

Mineralys Therapeutics (NASDAQ:MLYS) last announced its quarterly earnings results on Monday, November 10th. The company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.14. As a group, equities analysts predict that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current year.

Institutional Investors Weigh In On Mineralys Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Wellington Management Group LLP increased its position in Mineralys Therapeutics by 32.8% during the 1st quarter. Wellington Management Group LLP now owns 121,557 shares of the company’s stock valued at $1,930,000 after buying an additional 30,028 shares in the last quarter. Voya Investment Management LLC bought a new stake in Mineralys Therapeutics in the first quarter worth $255,000. Strs Ohio bought a new stake in Mineralys Therapeutics in the first quarter worth $359,000. Goldman Sachs Group Inc. boosted its stake in Mineralys Therapeutics by 166.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 298,395 shares of the company’s stock worth $4,739,000 after purchasing an additional 186,480 shares in the last quarter. Finally, XTX Topco Ltd purchased a new stake in Mineralys Therapeutics during the 1st quarter valued at about $219,000. Hedge funds and other institutional investors own 84.46% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. HC Wainwright raised their target price on shares of Mineralys Therapeutics from $52.00 to $56.00 and gave the stock a “buy” rating in a research report on Wednesday. The Goldman Sachs Group increased their price target on shares of Mineralys Therapeutics from $32.00 to $52.00 and gave the stock a “buy” rating in a research note on Tuesday, September 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Mineralys Therapeutics in a research report on Wednesday, October 8th. Wells Fargo & Company increased their target price on Mineralys Therapeutics from $50.00 to $55.00 and gave the stock an “overweight” rating in a research report on Tuesday. Finally, Bank of America raised their target price on Mineralys Therapeutics from $38.00 to $43.00 and gave the company a “buy” rating in a research note on Thursday, August 28th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Mineralys Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $46.67.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.